PSPN and metastatic neoplasm: While MMP-7 inhibitors previously failed in clinical trials for treatment of metastatic disease [39,40,41], the findings reported here point to new avenues to interfere with downstream activation of dyscohesion and migration resulting from MMP-7 cleavage of the PSPN Complex.